Is Rezum Water Vapour Therapy a feasible option for men with larger prostate glands?
BAUS ePoster online library. Sarkar S. 06/25/19; 259595; P9-9
Ms. Somita Sarkar
Ms. Somita Sarkar
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)
INTRODUCTION

Rezum water vapour therapy is a minimally invasive treatment for symptomatic BPH. The surgical treatment options for men with larger prostate glands are rather limited, and invariably involve a significant in-patient stay.

Methods

This study involves a prospective analysis of data for men undergoing Rezum comparing pre-treatment assessments with 3 months follow-up data. Gland volumes in the cohort ranged from between 20 and 120ml. We compared men with glands <80mls and >80mls. Pre and post procedure assessments included validated questionnaires (IPSS with QoL, IIEF-5), urinary flow rate (Qmax), prostate volume and length of stay. 125 patients were included of whom 19 had gland volumes >80 mls.

Results
The mean IPSS before and 3 months after treatment for the cohort was 22.0 and 5.6 respectively (22.6 for small glands and 21.0 for large glands pre, p=0.44 and 5.6 vs. 5.7 post, p=0.89). The QoL scores in small and large glands were 4.4 and 4.3, p=0.83 pre-treatment and 1.4 vs. 1.0 post, p=0.44. There were no significant differences in flow rate or length of stay. A single patient in each group required bladder washout in theatre due to secondary haemorrhage. 6 patients in the small gland group were treated for UTI compared to 1 in the large gland group.

CONCLUSION

In this series there was no significant overall difference in early post treatment outcomes when comparing both groups. Further studies are necessary to determine a sensible 'upper limit' in gland size for those wishing to consider this new therapy.
INTRODUCTION

Rezum water vapour therapy is a minimally invasive treatment for symptomatic BPH. The surgical treatment options for men with larger prostate glands are rather limited, and invariably involve a significant in-patient stay.

Methods

This study involves a prospective analysis of data for men undergoing Rezum comparing pre-treatment assessments with 3 months follow-up data. Gland volumes in the cohort ranged from between 20 and 120ml. We compared men with glands <80mls and >80mls. Pre and post procedure assessments included validated questionnaires (IPSS with QoL, IIEF-5), urinary flow rate (Qmax), prostate volume and length of stay. 125 patients were included of whom 19 had gland volumes >80 mls.

Results
The mean IPSS before and 3 months after treatment for the cohort was 22.0 and 5.6 respectively (22.6 for small glands and 21.0 for large glands pre, p=0.44 and 5.6 vs. 5.7 post, p=0.89). The QoL scores in small and large glands were 4.4 and 4.3, p=0.83 pre-treatment and 1.4 vs. 1.0 post, p=0.44. There were no significant differences in flow rate or length of stay. A single patient in each group required bladder washout in theatre due to secondary haemorrhage. 6 patients in the small gland group were treated for UTI compared to 1 in the large gland group.

CONCLUSION

In this series there was no significant overall difference in early post treatment outcomes when comparing both groups. Further studies are necessary to determine a sensible 'upper limit' in gland size for those wishing to consider this new therapy.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies